Cameroon FY2020 Work Plan

The FY2020 work plan outlines the activities that are expected to be undertaken in Cameroon in the next fiscal year through USAID's Act to End NTDs | West program (Act | West), managed by FHI 360 and implemented in Cameroon by Helen Keller International. 

In Cameroon, the Central Coordination Unit of the Ministry of Health coordinates integrated control activities for priority preventive chemotherapy (PC) NTDs—lymphatic filariasis (LF), onchocerciasis (OV), schistosomiasis (SCH), soil-transmitted helminths (STH), and trachoma—at the national and regional levels. Three national programs are involved in the control and elimination of PC NTDs:

  • The National Program for OV Control (PNLO), which focuses on OV and LF
  • The National Program for Blindness Control (PNLCé), which focuses on trachoma
  • The National Program for SCH and STH control (PNLSHI)

According to Cameroon’s National Strategic Plan for NTDs, LF, trachoma and OV are targeted for elimination as a public health problem and SCH and STH are targeted for control. USAID’s Act to End NTDs | West program is helping the PNLO, PNLCé, PNSHI and health ministry to ensure that NTD elimination and control objectives are achieved and that progress is sustained by Cameroon in the long-term. This support includes management of trachomatous trichiasis, scale up of LF morbidity management, dossier development, mass treatments, and disease-specific assessments related to OV, LF, Trachoma, SCH and STH.

Cameroon FY2020 Act to End NTDs | West Program Work Plan
Type
Work Plan
Year of publication
Disease
All Preventive Chemotherapy NTDs
Country
All Countries, Cameroon
Focus Areas
Mass Drug Administration (MDA), MDA implementation, Community outreach, Drug procurement & supply chain support, Cross-border initiatives, Annual training for MDA, Support for NTD Sustainability, Advocacy and policies, Cross-sector collaboration, NTD governance, Strategic health information, NTD Capacity Building, Monitoring, Evaluation, Research, Learning and Adapting (MERLA), Disease-specific assessments, post-treatment surveillance, and related training, Disease & morbidity mapping & assessment, Learning & quality improvement, Data for decision-making, Operational research, Dossier development
Partners
FHI360, Helen Keller International